For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium includes access to the Zacks Style Scores as well.What are the Zacks Style Scores?D ...

Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Amedisys (AMED) and U.S. Physical Therapy (USPH) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and estimate r ...

Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Amedisys (AMED) and U.S. Physical Therapy (USPH) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies with positive estimate revision trends, and our Style Scores ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.It also includes access to the Zacks Style Scores.What are the Zacks Style Scores?Developed ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.It also includes access to the Zacks Style Scores.What are the Zacks Style Scores?The Zacks S ...

It has been about a month since the last earnings report for Amedisys (AMED) . Shares have added about 5.5% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Amedisys due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Amedisys Q4 Earnings Miss Estimates, Margins RiseAm ...

Amedisys, Inc. (AMED) reported adjusted earnings per share (EPS) of $1.03 in the first quarter of 2024, which topped 3% from the year-ago quarter’s $1.00 per share. The bottom line also beat the Zacks Consensus Estimate by 1.9%.The quarter’s adjustments include certain merger-related expenses and other (income)/expenses, net. GAAP EPS in the first quarter was 59 cents compared to 23 cents in the same period last year.Net service revenues totaled $571.4 million, up 2.7% year over year. The top line surpassed ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share AMED The NASDAQ Global Select Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECU ...

Amedisys (AMED) reported $571.41 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 2.7%. EPS of $1.03 for the same period compares to $1.00 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $564.58 million, representing a surprise of +1.21%. The company delivered an EPS surprise of +1.98%, with the consensus EPS estimate being $1.01.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Stre ...

Amedisys (AMED) came out with quarterly earnings of $1.03 per share, beating the Zacks Consensus Estimate of $1.01 per share. This compares to earnings of $1 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 1.98%. A quarter ago, it was expected that this home health care and hospice services provider would post earnings of $1.04 per share when it actually produced earnings of $0.94, delivering a surprise of -9.62%.Over the last ...